Viewing StudyNCT06448312

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-06-16 @ 11:50 AM
Last Modification Date: 2024-10-26 @ 3:31 PM
Study NCT ID: NCT06448312
Status: RECRUITING
Last Update Posted: 2024-06-07
First Post: 2024-06-03
Brief Title: A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co Ltd
Organization: Sichuan Kelun Pharmaceutical Research Institute Co Ltd
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Organization Data

Organization: Sichuan Kelun Pharmaceutical Research Institute Co Ltd
Class: INDUSTRY
Study ID: SKB264-Ⅲ-12
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co Ltd
Lead Sponsor Class: INDUSTRY
Responsible Party: None
Responsible Party Title: None
Responsible Party Type: SPONSOR
Responsible Party Affiliation: None
Old Name: None
Old Organization: None

Collaborators